- Home
- SYBT vs AKRO Comparison
SYBT vs AKRO Comparison
Compare SYBT & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SYBT
- AKRO
- Stock Information
- Founded
- SYBT 1904
- AKRO 2017
- Country
- SYBT United States
- AKRO United States
- Employees
- SYBT N/A
- AKRO N/A
- Industry
- SYBT Major Banks
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- SYBT Finance
- AKRO Health Care
- Exchange
- SYBT Nasdaq
- AKRO Nasdaq
- Market Cap
- SYBT 2.0B
- AKRO 2.0B
- IPO Year
- SYBT N/A
- AKRO 2019
- Fundamental
- Price
- SYBT $73.12
- AKRO $25.14
- Analyst Decision
- SYBT Hold
- AKRO Strong Buy
- Analyst Count
- SYBT 4
- AKRO 8
- Target Price
- SYBT $65.25
- AKRO $46.83
- AVG Volume (30 Days)
- SYBT 171.3K
- AKRO 842.7K
- Earning Date
- SYBT 01-27-2025
- AKRO 02-27-2025
- Dividend Yield
- SYBT 1.67%
- AKRO N/A
- EPS Growth
- SYBT N/A
- AKRO N/A
- EPS
- SYBT 3.63
- AKRO N/A
- Revenue
- SYBT $331,807,000.00
- AKRO N/A
- Revenue This Year
- SYBT N/A
- AKRO N/A
- Revenue Next Year
- SYBT $7.31
- AKRO N/A
- P/E Ratio
- SYBT $20.14
- AKRO N/A
- Revenue Growth
- SYBT 1.02
- AKRO N/A
- 52 Week Low
- SYBT $42.35
- AKRO $15.32
- 52 Week High
- SYBT $79.79
- AKRO $37.00
- Technical
- Relative Strength Index (RSI)
- SYBT 53.77
- AKRO 41.89
- Support Level
- SYBT $70.92
- AKRO $21.34
- Resistance Level
- SYBT $73.41
- AKRO $28.94
- Average True Range (ATR)
- SYBT 2.18
- AKRO 1.38
- MACD
- SYBT 0.26
- AKRO -0.27
- Stochastic Oscillator
- SYBT 96.18
- AKRO 49.67
About SYBT Stock Yards Bancorp Inc.
Stock Yards Bancorp Inc operates as a bank. The bank has two reportable operating segments namely Commercial Banking and Wealth Management and trust. Its services include loan and deposit services, cash management services, securities brokerage activities, mortgage origination, and others. It generates a majority of its revenue from the Commercial Banking segment.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.